The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation
Open accessAbstract
Gene therapy is a promising modality for the treatment of inherited and acquired cardiovascular diseases. The identification of the molecular pathways involved in the pathophysiology of heart failure and other associated cardiac diseases led to encouraging preclinical gene therapy studies in small and large animal models. However, the initial clinical results yielded only modest or no improvement in clinical endpoints. The presence of neutralizing antibodies and cellular immune responses directed against the viral vector and/or the gene-modified cells, the insufficient gene expression levels, and the limited gene transduction efficiencies accounted for the overall limited clinical improvements. Nevertheless, further improvements of the gene delivery technology and a better understanding of the underlying biology fostered renewed interest in gene therapy for heart failure. In particular, improved vectors based on emerging cardiotropic serotypes of the adeno-associated viral vector (AAV) are particularly well suited to coax expression of therapeutic genes in the heart. This led to new clinical trials based on the delivery of the sarcoplasmic reticulum Ca(2+)-ATPase protein (SERCA2a). Though the first clinical results were encouraging, a recent Phase IIb trial did not confirm the beneficial clinical outcomes that were initially reported. New approaches based on S100A1 and adenylate cyclase 6 are also being considered for clinical applications. Emerging paradigms based on the use of miRNA regulation or CRISPR/Cas9-based genome engineering open new therapeutic perspectives for treating cardiovascular diseases by gene therapy. Nevertheless, the continuous improvement of cardiac gene delivery is needed to allow the use of safer and more effective vector doses, ultimately bringing gene therapy for heart failure one step closer to reality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
The Sympathetic Nervous System in Heart Failure
Triposkiadis, F., Karayannis, G., Giamouzis, G., Skoularigis, J., Louridas, G., & Butler, J. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.015 · Cited by 978 · cited 19×
“These preclinical data support the use of S100A1 as a gene therapy modality in patients with HF.”
BackgroundInfluentialImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 2×
“the surface of transduced target cells may curtail long-term gene expression after immune rejection of the gene-modified target cells.(20) The use of transient immune suppression and/or AAV capsid variants”
BackgroundTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · cited 3×
“persistent transgene expression in a wide range of target tissues, including the heart.(39) Since they provoke much less inflammation compared”
BackgroundInagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610
Gheorghiade, M., & Pang, P. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.041 · Cited by 600
Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
Ding, Q., Strong, A., Patel, K. M., Ng, S.-L., Gosis, B. S., Regan, S. N., Cowan, C. A., Rader, D. J., & Musunuru, K. (2014) · Circulation Research · doi:10.1161/circresaha.115.304351 · Cited by 522
Jaski, B. E., Jessup, M. L., Mancini, D. M., Cappola, T. P., Pauly, D. F., Greenberg, B., Borow, K., Dittrich, H., Zsebo, K. M., & Hajjar, R. J. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.01.013 · Cited by 457
Zsebo, K., Yaroshinsky, A., Rudy, J. J., Wagner, K., Greenberg, B., Jessup, M., & Hajjar, R. J. (2014) · Circulation Research · doi:10.1161/circresaha.113.302421 · Cited by 315
Pleger, S. T., Shan, C., Ksienzyk, J., Bekeredjian, R., Boekstegers, P., Hinkel, R., Schinkel, S., Leuchs, B., Ludwig, J., Qiu, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002097 · Cited by 234 · cited 2×
“The therapeutic effects of S100A1 were preserved during b-adrenergic antagonist treatment with metoprolol, improving its cardiac reverse remodelling, ionotropic action, and anti-arrhythmic effects.101 Intracoronary adenovirusmediated S100A1 gene delivery in a rat model of post-MI improved myocardial contractility and…”
BackgroundEfficient in vivo gene expression by trans-splicing adeno-associated viral vectors
Lai, Y., Yue, Y., Liu, M., Ghosh, A., Engelhardt, J. F., Chamberlain, J. S., & Duan, D. (2005) · Nature Biotechnology · doi:10.1038/nbt1153 · Cited by 224
AAV transcytosis through barrier epithelia and endothelium
Di Pasquale, G., & Chiorini, J. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.007 · Cited by 121
Biosafety of Adenoviral Vectors
Chuah, M. K. L., Collen, D., & VandenDriessche, T. (2003) · Current Gene Therapy · doi:10.2174/1566523034578140 · Cited by 71 · cited 1×
“hepatocytes, antigen-presenting cells).(33) Consequently, the utility of Ad vectors in cardiovascular gene therapy trials in humans must be carefully evaluated.”
BackgroundSelf-citationBeeri, R., Chaput, M., Guerrero, J. L., Kawase, Y., Yosefy, C., Abedat, S., Karakikes, I., Morel, C., Tisosky, A., Sullivan, S., et al. (2010) · Circulation: Heart Failure · doi:10.1161/circheartfailure.109.891184 · Cited by 69
Retrovirus and lentivirus vector design and methods of cell conditioning
Cooray, S., Howe, S. J., & Thrasher, A. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00003-x · Cited by 65
Cited by
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles
Bonora, M., Wieckowski, M. R., Sinclair, D. A., Kroemer, G., Pinton, P., & Galluzzi, L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0074-0 · Cited by 294
Liang, G., Kan, S., Zhu, Y., Feng, S., Feng, W., & Gao, S. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s154458 · Cited by 276
Applications of Gene Therapy in Cardiomyopathies
Argiro, A., Bui, Q., Hong, K. N., Ammirati, E., Olivotto, I., & Adler, E. (2024) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.09.015 · Cited by 59
Metadata
- Authors
- Rincon, M. Y., VandenDriessche, T., & Chuah, M. K.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-08-03
- Volume
- 108
- Issue
- 1
- Pages
- 4-20
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W1887024293
- Cited by
- 167
- References
- 18
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.